Levonadifloxacin, a novel benzoquinolizine fluoroquinolone modulates lipopolysaccharide induced inflammatory responses in human whole blood assay and murine acute lung injury model

Fluoroquinolones are reported to possess immunomodulatory activity; hence a novel benzoquinolizine fluoroquinolone levonadifloxacin was evaluated in lipopolysaccharide (LPS) stimulated human whole blood (HWB) and mice acute lung injury (ALI) models. Levonadifloxacin significantly mitigated the inflammatory responses in HWB assay through inhibition of pro-inflammatory cytokines and in ALI model by lowering lung total white blood cell count, myeloperoxidase and cytokines levels. The immunomodulatory effect of levonadifloxacin along with promising antibacterial activity is expected to provide clinical benefits in the treatment of infections.